{
    "@graph": [
        {
            "@id": "https://www.tib.eu/de/suchen/id/TIBKAT%3A1738406407",
            "@type": "bibo:Book",
            "P1053": "1 Online-Ressource",
            "http://purl.org/dc/elements/1.1/contributor": [
                "Lo, Andrew W.",
                "Xiao, Danying",
                "Xu, Qingyang"
            ],
            "creator": [
                "National Bureau of Economic Research",
                "Chaudhuri, Shomesh"
            ],
            "description": [
                "illustrations (black and white)",
                "Campusweiter Zugriff (Universit\u00e4t Hannover) - Vervielf\u00e4ltigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots."
            ],
            "identifier": [
                "(doi)10.3386/w27175",
                "(ppn)1738406407",
                "(firstid)KEP:059521015"
            ],
            "publisher": "National Bureau of Economic Research",
            "subject": "(classificationName=linseach:automatic)mat",
            "title": "Bayesian Adaptive Clinical Trials for Anti\u2010Infective Therapeutics during Epidemic Outbreaks",
            "abstract": "In the midst of epidemics such as COVID-19, therapeutic candidates are unlikely to be able to complete the usual multiyear clinical trial and regulatory approval process within the course of an outbreak. We apply a Bayesian adaptive patient-centered model--which minimizes the expected harm of false positives and false negatives--to optimize the clinical trial development path during such outbreaks. When the epidemic is more infectious and fatal, the Bayesian-optimal sample size in the clinical trial is lower and the optimal statistical significance level is higher. For COVID-19 (assuming a static <i>R</i><sub>0</sub> - 2 and initial infection percentage of 0.1%), the optimal significance level is 7.1% for a clinical trial of a nonvaccine anti-infective therapeutic and 13.6% for that of a vaccine. For a dynamic <i>R</i><sub>0</sub> decreasing from 3 to 1.5, the corresponding values are 14.4% and 26.4%, respectively. Our results illustrate the importance of adapting the clinical trial design and the regulatory approval process to the specific parameters and stage of the epidemic",
            "contributor": "Technische Informationsbibliothek (TIB)",
            "isPartOf": "(collectioncode)ZDB-194-NBW",
            "issued": "2020",
            "language": "http://id.loc.gov/vocabulary/iso639-1/en",
            "license": "open access",
            "medium": "rda:termList/RDACarrierType/1018",
            "volume": "no. w27175",
            "isLike": "doi:10.3386/w27175",
            "P30128": "NBER working paper series",
            "P60163": "Cambridge, Mass"
        }
    ],
    "@id": "urn:x-arq:DefaultGraphNode",
    "@context": {
        "volume": "http://purl.org/ontology/bibo/volume",
        "language": {
            "@id": "http://purl.org/dc/terms/language",
            "@type": "@id"
        },
        "contributor": "http://purl.org/dc/terms/contributor",
        "P30128": "http://www.rdaregistry.info/Elements/m/#P30128",
        "abstract": "http://purl.org/dc/terms/abstract",
        "isLike": {
            "@id": "http://umbel.org/umbel#isLike",
            "@type": "@id"
        },
        "issued": "http://purl.org/dc/terms/issued",
        "isPartOf": "http://purl.org/dc/terms/isPartOf",
        "identifier": "http://purl.org/dc/elements/1.1/identifier",
        "P60163": "http://www.rdaregistry.info/Elements/u/#P60163",
        "description": "http://purl.org/dc/elements/1.1/description",
        "creator": "http://purl.org/dc/elements/1.1/creator",
        "license": "http://purl.org/dc/terms/license",
        "medium": {
            "@id": "http://purl.org/dc/terms/medium",
            "@type": "@id"
        },
        "publisher": "http://purl.org/dc/elements/1.1/publisher",
        "P1053": "http://iflastandards.info/ns/isbd/elements/P1053",
        "subject": "http://purl.org/dc/elements/1.1/subject",
        "title": "http://purl.org/dc/elements/1.1/title",
        "umbel": "http://umbel.org/umbel#",
        "rdau": "http://www.rdaregistry.info/Elements/u/#",
        "owl": "http://www.w3.org/2002/07/owl#",
        "dcterms": "http://purl.org/dc/terms/",
        "bibo": "http://purl.org/ontology/bibo/",
        "rdam": "http://www.rdaregistry.info/Elements/m/#",
        "gnd": "http://d-nb.info/gnd/",
        "isbd": "http://iflastandards.info/ns/isbd/elements/",
        "rda": "http://rdvocab.info/",
        "doi": "https://doi.org/"
    }
}